Monograph Details
|
|
Cardiovascular System
> Hyperlipoproteinemias
|
|
LOVAZA |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Lipid-regulating agent. |
| Generic Name |
|
Omega-3-acid ethyl esters 1g; caps; contains α-tocopherol 4mg/cap. |
| Indications |
|
Adjunct to diet to reduce very high (≥500mg/dL) triglyceride levels in adults. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: 4g daily; may take as 4g once daily or as 2g twice daily. |
| Precautions |
|
Obtain baseline triglycerides (TG); monitor TG, LDL-C, and ALT during therapy; discontinue if response is inadequate after 2 months. Exclude and/or treat secondary causes of hypertriglyceridema (eg, hypothyroidism, diabetes, alcoholism, obesity, medications). Fish allergy. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May potentiate anticoagulants; monitor. |
| Adverse Reactions |
|
Infection, flu syndrome, eructation, dyspepsia, rash, taste perversion, back pain, angina pectoris, increased ALT, LDL-C (monitor). |
| Extra Text |
|
Note: This product was formerly named Omacor. |
| How Supplied |
|
Caps—60, 120 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
